Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 125273
Published online Nov 15, 2026. doi: 10.4251/wjgo.125273
Published online Nov 15, 2026. doi: 10.4251/wjgo.125273
Table 3 Main drugs used in the treatment of ulcerative colitis: Doses, mechanisms of action, and therapeutic response
| Treatment | Dose scheme | Mechanism | Response | Ref. | |
| 5-ASA | Mesalazine | Induction: 2.4-4.8 g/day | Anti-inflammatory by activating PPAR-y receptors | UC: Clinical and endoscopic remission | [10,89,167,168] |
| Maintenance: 1.5-2.0 g/day | CD: Poor response | ||||
| Glucocorticoids | Betamethasone | Induction: 5 mg/day | Immunosuppressors by reduced expression of IL-1, IL-1β and IL-8, TGF-β3 and IL-10 | UC: Clinical and endoscopic remission | [167,169,170] |
| Budesonide MMX | Induction and maintenance: 9 mg/day | ||||
| Hydrocortisone | Induction: 356 mg/day | CD: Clinical remission | |||
| Prednisolone | Induction: ≥ 30 mg/day | ||||
| Thiopurines | Azathioprine | Induction and maintenance: 1.5 to 2.5 mg/kg/day | Immunosupressor. Targets Rac1 activation and inhibits gut T cells | UC: Poor response in active disease. Used for remission maintenance | [171-174] |
| CD: Clinical remission | |||||
| 6-mercaptopurine | Induction and maintenance: 1-1.5 mg/kg/day | Immunosuppressor. Inhibits purine synthesis | UC: Remission maintenance | [175,176] | |
| CD: Clinical remission or significant improvement | |||||
| Methotrexate | Induction and maintenance: 25 mg/week | Immunosupressor inhibits purine synthesis | UC: Poor response | [177-179] | |
| Decrease in production of cytokines and eicosanoids | CD: Clinical remission and maintenance | ||||
- Citation: Delgado-Gonzalez P, Quiroz-Reyes AG, Simental-Mendía MA, Loaiza-Gutiérrez VL, Garza-Treviño EN. Inflammation-driven carcinogenesis in ulcerative colitis: Molecular and immunological pathways. World J Gastrointest Oncol 2026; 18(11): 125273
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/125273.htm
- DOI: https://dx.doi.org/10.4251/wjgo.125273